Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer

Mark Rodgers; Matthew James Walton; Sumayya Anwer; Mark Stephen Corbett; Martin Wanyoike Njoroge; Helen Athena Fulbright; Raj Naik; Melanie Powell; Alison Jane Eastwood; Robert Hodgson

Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer

Mark Rodgers, Matthew James Walton, Sumayya Anwer, Mark Stephen Corbett, Martin Wanyoike Njoroge, Helen Athena Fulbright, Raj Naik, Melanie Powell, Alison Jane Eastwood, Robert Hodgson^*

^*Corresponding author for this work

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Original language	English
Publisher	National Institute for Health and Care Excellence
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 29 Mar 2023

Access to Document

https://www.nice.org.uk/guidance/ta939/documents/committee-papers-2

Cite this

Rodgers, M., Walton, M. J., Anwer, S., Corbett, M. S., Njoroge, M. W., Fulbright, H. A., Naik, R., Powell, M., Eastwood, A. J., & Hodgson, R. (2023). Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta939/documents/committee-papers-2

@book{acc19997ff07488b8965055a6003d66a,

title = "Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer",

author = "Mark Rodgers and Walton, {Matthew James} and Sumayya Anwer and Corbett, {Mark Stephen} and Njoroge, {Martin Wanyoike} and Fulbright, {Helen Athena} and Raj Naik and Melanie Powell and Eastwood, {Alison Jane} and Robert Hodgson",

year = "2023",

month = mar,

day = "29",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

Rodgers, M , Walton, MJ , Anwer, S , Corbett, MS , Njoroge, MW , Fulbright, HA, Naik, R, Powell, M, Eastwood, AJ & Hodgson, R 2023, Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer. National Institute for Health and Care Excellence. <https://www.nice.org.uk/guidance/ta939/documents/committee-papers-2>

Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer. / Rodgers, Mark ; Walton, Matthew James ; Anwer, Sumayya et al.
National Institute for Health and Care Excellence, 2023.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer

AU - Rodgers, Mark

AU - Walton, Matthew James

AU - Anwer, Sumayya

AU - Corbett, Mark Stephen

AU - Njoroge, Martin Wanyoike

AU - Fulbright, Helen Athena

AU - Naik, Raj

AU - Powell, Melanie

AU - Eastwood, Alison Jane

AU - Hodgson, Robert

PY - 2023/3/29

Y1 - 2023/3/29

M3 - Commissioned report

BT - Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer

PB - National Institute for Health and Care Excellence

ER -